Among 772 121 patients with type 2 diabetes in the MDV database in the study period, a total of 5247 satisfied the eligibility criteria, of which 990 were treated with an SGLT2 inhibitor and 4257 were treated with a DPP‐4 inhibitor (Figure 1). Here, SLC5A2 is linked to type 2 diabetes mellitus.